Making a Difference in the health of moms & babies

Sera Prognostics was founded to develop diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera’s tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans.

The company has completed Its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study that clinically validated the PreTRM test as highly predictive of preterm birth early in pregnancy. To read more about this study, and its subsequent publication, click here.

The company’s proteomic predictor of premature birth risk—the PreTRM® Test for Risk Management-became commercially available in the U.S. in early 2016.

Vision: Early Prediction of Premature birth, preeclampsia, and other pregnancy complications

To be a global leader in high-value women’s health diagnostics, delivering pivotal information to patients and physicians that will improve the health of pregnant women and newborns and simultaneously improve the economics of healthcare.

“With one simple blood test, proteomic science gives us early, accurate prediction of premature birth. With that comes hope—the hope of finally making a big difference for women and their babies.”

M. Sean Esplin, MD, Company Founder